Active — Not RecruitingPhase 1

Study of the Safety and Feasibility of Psilocybin in Adults With Methamphetamine Use Disorder

United States12 participantsStarted 2023-03-03

Plain-language summary

The purpose of this research study is to investigate the safety and feasibility of two (2) oral doses of psilocybin when combined with behavioral support for methamphetamine use disorder (MUD). Participants have a diagnosis of methamphetamine use disorder (MUD). Participants can expect to be actively engaged in the study for up to 26 weeks.

Who can participate

Age range25 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Diagnosis of methamphetamine use disorder Exclusion Criteria: * Positive urine pregnancy at any time point during screening or study participation * Inadequately treated hypertension, defined as 2 blood pressure readings, 10 minutes apart, of greater than 140/90 mmHg systolic/diastolic * Current acute coronary syndrome or angina * History of heart transplant or stroke * Current use of and inability or unwillingness to taper off of medications that may interact with psilocybin * Current insulin dependence, due to Type I or Type II diabetes

What they're measuring

Incidence of serious adverse events associated with oral psilocybin

Timeframe: Up to 26 weeks

Trial details

NCT IDNCT05322954

SponsorUniversity of Wisconsin, Madison

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-05

View on ClinicalTrials.gov More Methamphetamine Use Disorder trials